Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION. Kato T, Yang JC, Ahn MJ, Sakai H, et al. Br J Cancer 2024;130:1679-1686.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kato T, Yang JC, Ahn MJ, Sakai H, et al. Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION. Br J Cancer 2024;130:1679-1686.
PMID: 38575731